Literature DB >> 25912496

Prostate Cancer Volume Estimation by Combining Magnetic Resonance Imaging and Targeted Biopsy Proven Cancer Core Length: Correlation with Cancer Volume.

Toru Matsugasumi1, Eduard Baco2, Suzanne Palmer3, Manju Aron4, Yoshinobu Sato5, Norio Fukuda5, Evren Süer2, Jean-Christophe Bernhard2, Hideo Nakagawa1, Raed A Azhar6, Inderbir S Gill2, Osamu Ukimura7.   

Abstract

PURPOSE: Multiparametric magnetic resonance imaging often underestimates or overestimates pathological cancer volume. We developed what is to our knowledge a novel method to estimate prostate cancer volume using magnetic resonance/ultrasound fusion, biopsy proven cancer core length.
MATERIALS AND METHODS: We retrospectively analyzed the records of 81 consecutive patients with magnetic resonance/ultrasound fusion, targeted biopsy proven, clinically localized prostate cancer who underwent subsequent radical prostatectomy. As 7 patients each had 2 visible lesions on magnetic resonance imaging, 88 lesions were analyzed. The dimensions and estimated volume of visible lesions were calculated using apparent diffusion coefficient maps. The modified formula to estimate cancer volume was defined as the formula of vertical stretching in the anteroposterior dimension of the magnetic resonance based 3-dimensional model, in which the imaging estimated lesion anteroposterior dimension was replaced by magnetic resonance/ultrasound targeted, biopsy proven cancer core length. Agreement of pathological cancer volume with magnetic resonance estimated volume or the novel modified volume was assessed using a Bland-Altman plot.
RESULTS: Magnetic resonance/ultrasound fusion, biopsy proven cancer core length was a stronger predictor of the actual pathological cancer anteroposterior dimension than magnetic resonance estimated lesion anteroposterior dimension (r = 0.824 vs 0.607, each p <0.001). Magnetic resonance/ultrasound targeted, biopsy proven cancer core length correlated with pathological cancer volume (r = 0.773, p <0.001). The modified formula to estimate cancer volume demonstrated a stronger correlation with pathological cancer volume than with magnetic resonance estimated volume (r = 0.824 vs 0.724, each p <0.001). Agreement of modified volume with pathological cancer volume was improved over that of magnetic resonance estimated volume on Bland-Altman plot analysis. Predictability was more enhanced in the subset of lesions with a volume of 2 ml or less (ie if spherical, the lesion was approximately 16 mm in diameter).
CONCLUSIONS: Combining magnetic resonance estimated cancer volume with magnetic resonance/ultrasound fusion, biopsy proven cancer core length improved cancer volume predictability.
Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  biopsy; magnetic resonance imaging; prognosis; prostatic neoplasms; tumor burden

Mesh:

Year:  2015        PMID: 25912496      PMCID: PMC9083553          DOI: 10.1016/j.juro.2015.04.075

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.600


  9 in total

1.  Prostate MRI: evaluating tumor volume and apparent diffusion coefficient as surrogate biomarkers for predicting tumor Gleason score.

Authors:  Olivio F Donati; Asim Afaq; Hebert Alberto Vargas; Yousef Mazaheri; Junting Zheng; Chaya S Moskowitz; Hedvig Hricak; Oguz Akin
Journal:  Clin Cancer Res       Date:  2014-05-21       Impact factor: 12.531

2.  Tumor target volume for focal therapy of prostate cancer-does multiparametric magnetic resonance imaging allow for a reliable estimation?

Authors:  F Cornud; Gaby Khoury; Naim Bouazza; Frederic Beuvon; Michael Peyromaure; Thierry Flam; Marc Zerbib; Paul Legmann; Nicolas B Delongchamps
Journal:  J Urol       Date:  2013-12-12       Impact factor: 7.450

3.  Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging.

Authors:  Fergus V Coakley; John Kurhanewicz; Ying Lu; Kirk D Jones; Mark G Swanson; Silvia D Chang; Peter R Carroll; Hedvig Hricak
Journal:  Radiology       Date:  2002-04       Impact factor: 11.105

4.  Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings.

Authors:  Arnauld Villers; Philippe Puech; Damien Mouton; Xavier Leroy; Charles Ballereau; Laurent Lemaitre
Journal:  J Urol       Date:  2006-12       Impact factor: 7.450

5.  Comparison of real-time elastography and multiparametric MRI for prostate cancer detection: a whole-mount step-section analysis.

Authors:  Daniel Junker; Georg Schäfer; Conrad Kobel; Christian Kremser; Jasmin Bektic; Werner Jaschke; Friedrich Aigner
Journal:  AJR Am J Roentgenol       Date:  2014-03       Impact factor: 3.959

6.  Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer.

Authors:  Veeru Kasivisvanathan; Robert Dufour; Caroline M Moore; Hashim U Ahmed; Mohamed Abd-Alazeez; Susan C Charman; Alex Freeman; Clare Allen; Alex Kirkham; Jan van der Meulen; Mark Emberton
Journal:  J Urol       Date:  2012-10-11       Impact factor: 7.450

7.  Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume.

Authors:  Yousef Mazaheri; Hedvig Hricak; Samson W Fine; Oguz Akin; Amita Shukla-Dave; Nicole M Ishill; Chaya S Moskowitz; Joanna E Grater; Victor E Reuter; Kristen L Zakian; Karim A Touijer; Jason A Koutcher
Journal:  Radiology       Date:  2009-08       Impact factor: 11.105

8.  Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies.

Authors:  Nicolas Barry Delongchamps; Michaël Peyromaure; Alexandre Schull; Frédéric Beuvon; Naïm Bouazza; Thierry Flam; Marc Zerbib; Naira Muradyan; Paul Legman; François Cornud
Journal:  J Urol       Date:  2012-10-08       Impact factor: 7.450

9.  Multiparametric MRI for prostate cancer localization in correlation to whole-mount histopathology.

Authors:  Sofie Isebaert; Laura Van den Bergh; Karin Haustermans; Steven Joniau; Evelyne Lerut; Liesbeth De Wever; Frederik De Keyzer; Tom Budiharto; Pieter Slagmolen; Hendrik Van Poppel; Raymond Oyen
Journal:  J Magn Reson Imaging       Date:  2012-11-21       Impact factor: 4.813

  9 in total
  13 in total

Review 1.  Techniques and Outcomes of MRI-TRUS Fusion Prostate Biopsy.

Authors:  Masatomo Kaneko; Dordaneh Sugano; Amir H Lebastchi; Vinay Duddalwar; Jamal Nabhani; Christopher Haiman; Inderbir S Gill; Giovanni E Cacciamani; Andre Luis Abreu
Journal:  Curr Urol Rep       Date:  2021-03-22       Impact factor: 3.092

2.  Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology.

Authors:  Alan Priester; Shyam Natarajan; Pooria Khoshnoodi; Daniel J Margolis; Steven S Raman; Robert E Reiter; Jiaoti Huang; Warren Grundfest; Leonard S Marks
Journal:  J Urol       Date:  2016-07-30       Impact factor: 7.450

Review 3.  Spatial Tracking of Targeted Prostate Biopsy Locations: Moving Towards Effective Focal Partial Prostate Gland Ablation with Improved Treatment Planning.

Authors:  Steven Sidelsky; Shaan Setia; Srinivas Vourganti
Journal:  Curr Urol Rep       Date:  2017-10-18       Impact factor: 3.092

4.  Can MRI/TRUS fusion targeted biopsy replace saturation prostate biopsy in the re-evaluation of men in active surveillance?

Authors:  Pietro Pepe; Antonio Garufi; Giandomenico Priolo; Michele Pennisi
Journal:  World J Urol       Date:  2015-12-23       Impact factor: 4.226

5.  Impact of prostate-specific antigen screening on tumor size in patients with prostate cancer in a super-aging district in Kyoto, Japan.

Authors:  Toru Matsugasumi; Koji Okihara; Masashi Tsujimoto; Osamu Sato; Tetsuya Imura; Yasuhiro Yamada; Atsuko Fujihara; Takumi Shiraishi; Fumiya Hongo; Osamu Ukimura
Journal:  Int J Clin Oncol       Date:  2021-09-19       Impact factor: 3.402

6.  Serial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: Incremental Value.

Authors:  Ely R Felker; Jason Wu; Shyam Natarajan; Daniel J Margolis; Steven S Raman; Jiaoti Huang; Fred Dorey; Leonard S Marks
Journal:  J Urol       Date:  2015-12-07       Impact factor: 7.450

7.  Cancer core length from targeted biopsy: an index of prostate cancer volume and pathological stage.

Authors:  Demetrios N Simopoulos; Anthony E Sisk; Alan Priester; Ely R Felker; Lorna Kwan; Merdie K Delfin; Robert E Reiter; Leonard S Marks
Journal:  BJU Int       Date:  2019-02-24       Impact factor: 5.969

8.  Prostate cancer measurements on serial MRI during active surveillance: it's time to be PRECISE.

Authors:  Francesco Giganti; Vasilis Stavrinides; Armando Stabile; Elizabeth Osinibi; Clement Orczyk; Jan Philipp Radtke; Alex Freeman; Aiman Haider; Shonit Punwani; Clare Allen; Mark Emberton; Alex Kirkham; Caroline M Moore
Journal:  Br J Radiol       Date:  2020-09-21       Impact factor: 3.039

9.  Automatic segmentation of prostate MRI using convolutional neural networks: Investigating the impact of network architecture on the accuracy of volume measurement and MRI-ultrasound registration.

Authors:  Nooshin Ghavami; Yipeng Hu; Eli Gibson; Ester Bonmati; Mark Emberton; Caroline M Moore; Dean C Barratt
Journal:  Med Image Anal       Date:  2019-09-11       Impact factor: 8.545

10.  Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression.

Authors:  Ryan Stuchbery; Geoff Macintyre; Marek Cmero; Laurence M Harewood; Justin S Peters; Anthony J Costello; Christopher M Hovens; Niall M Corcoran
Journal:  Oncotarget       Date:  2016-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.